Bain Capital Life Sciences — Full Portfolio

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more

BiotechCambridge, US

Joshua Cohen(Executive Officer, Director)Justin Klee(Director)

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

BiotechWestlake Village, US

Alexander Asam(Director)Ricky Sun(Director)Todd Franklin Watanabe(Executive Officer, Director)

BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsRA CapitalFrazier Life Sciences

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)

BoardBruno Lucidi(Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)

Co-investorsRA Capital

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)

Co-investors3E Bioventures CapitalNextech InvestRA Capital

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess BiotechnologyAtlas VentureForesite CapitalFrazier Life SciencesOrbiMed

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in

BoardStuart Lawson(Director)

Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US

Christopher K. Zarins(Executive Officer, Director)Charles A. Taylor(Executive Officer, Director)Nicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)H. Baird Radford, III(Executive Officer)John Farquharin

Co-investorsBlue Venture FundsEmergent Medical Partners, LLPKhosla VenturesLifeforce CapitalLotus CapitalSilver Lake Partners+1 more

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsForesite CapitalMRL Ventures FundPremji Invest

Kestra Medical develops wearable defibrillator technology aimed at protecting patients at risk of sudden cardiac arrest through rapid defibrillation.

HardwareHealthtechMedical Devices

Co-investorsAndera PartnersLongitude Capital

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAtlas VentureAvoro Capital AdvisorsBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+3 more

BiotechEmeryville, US

Brian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)James Chung(Executive Officer)

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in

Co-investorsCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture PartnersRA Capital+1 more

Co-investorsForesite Capital

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Co-investorsForesite CapitalNextech InvestThird Rock Ventures

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.

BiotechHealthtechMedical DevicesAustin, US

Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)Mike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)Richard J. Hawkins(Director)An van Es-Johansson(Director)Ricky Sun(Director)

Co-investorsCentral Texas Angel NetworkGreen Park & Golf VenturesKeiretsu ForumMoore Venture PartnersNew Enterprise Associates (NEA)

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.

BiotechHealthtech

Rand Sutherlandin

Co-investorsAccess BiotechnologyDecheng CapitalOrbiMedTCG Crossover

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)Alex Martin(Chief Executive Officer)

Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+8 more

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Michael Naill(Senior Vice President, Process and Product Development)Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)

Co-investorsThird Rock VenturesBiotechnology Value FundGV (Google Ventures)

Swixx BioPharma is a commercialization partner that acts as the local subsidiary for biopharma, OTC, and medical device companies in markets they choose not to enter directly, handling market access, regulatory, and commercial operations without its own R&D or manufacturing.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsHBM PartnersMérieux Equity PartnersSK Capital Partners

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

Robin Walker(Executive Officer)Christopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)

BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsARCH Venture PartnersGV (Google Ventures)

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)in

Board seatNicholas DowningAdam M. Koppel· per SEC Form D

Co-investorsBain CapitalNEA SecondaryPolaris PartnersThird Rock Ventures

JenaValve manufactures the Trilogy Transcatheter Heart Valve System, an FDA-approved device for treating severe aortic regurgitation in high-risk patients who cannot undergo surgical valve replacement.

HealthtechMedical DevicesIrvine, US

Victoria Carr-Brendel(Executive Officer, Director)Hans-Reiner Figulla(Director)David Drachman(Executive Officer, Director)

BoardArnd Kaltofen(Director)inErik Amble(Director)Peter Barrett(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsAndera PartnersVI Partners

Vernon Hills, US

Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)Neal Campbell(Executive Officer)Christina Rother(Executive Officer)

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBlue Sea CapitalBootstrap EuropeClayton Dubilier & RiceCore Venture Capital+12 more

Co-investorsSR One Capital Management

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworthAlly Bridge Group+2 more

Affera develops a medical technology platform for treating cardiac arrhythmias, including atrial fibrillation, using innovative ablation solutions.

HealthtechMedical DevicesNewton, US

Doron Harlev(CEO, Founder)

Co-investorsElysia Capital

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)Kamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsEcoR1 CapitalForesite Capital

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsRA CapitalSofinnova Ventures

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)

Co-investorsSofinnova VenturesTCG Crossover

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)Thomas Wiggans(Director)Ricky Sun(Director)Ted Yednock(Executive Officer)

Co-investorsCorrelation VenturesNew Enterprise Associates (NEA)Clarus

Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.

Sector AgnosticBoston, US

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBCI

Bain Capital Credit is a credit investment manager that evaluates opportunities across the credit spectrum, offering commingled funds and separate accounts with varying liquidity parameters, asset exposures, and geographic concentrations.

Fintech

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Bain Capital Special Situations provides customized capital solutions across credit, private equity, and real assets, structuring investments for individual opportunities with a focus on downside protection.

Fintech

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Co-investorsBain Capital Tech OpportunitiesBain Capital VentureBlue Haven Initiative

Bain Capital Real Estate is a real estate investment platform that applies a value-add approach to complex, demand-driven assets.

PropTech

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Beeline provides a Vendor Management System (VMS) and extended workforce platform that helps enterprises manage their non-employee and external labor, covering compliance, cost control, and risk.

Enterprise SoftwareFuture of WorkHR TechSaaS

Co-investorsAcadian Ventures Management, Llc

Beeline Medicines is a clinical-stage biotechnology company developing precision therapies that target the underlying drivers of immune dysfunction for people living with autoimmune and inflammatory diseases such as lupus and psoriasis.

BiotechHealthtechStamford, US

Co-investorsBain Capital

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureJanus Henderson InvestorsLAVOmega FundsvenBio Global StrategicvenBio Partners+1 more

CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.

BiotechHealthtechMedical DevicesAuburndale, US

Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)Leslie Teso-Lichtman(Executive Officer)Frederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)

Co-investorsFrazier Life Sciences

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)

Co-investors5AM VenturesAisling CapitalFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Co-investorsAvoro Capital AdvisorsVenrockThe Column GroupThird Rock Ventures

The site presents corporate and investor news relating to Novo Nordisk, a pharmaceutical company, including financial reports and clinical trial results for products such as GLP-1 medicines and the hemophilia A treatment denecimig (Mim8).

BiotechHealthtech

Co-investorsAccess Biotechnology

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechMedical Devices

Co-investorsParagon Biosciences LLC

Global company developing next-generation eye disease therapies; acquired by Merck & Co.

Co-investorsJeito CapitalMRL Ventures FundSV Health Investors

FemTechHealthtechMedical DevicesRedwood City, US

Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)Tom Rodgers(Director)

BoardKen Haas(Director)Jonathan MacQuitty(Director)inMike Carusi(Director)

Co-investorsAmzak HealthEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz VenturesLightstone Ventures+5 more

Chronus (at imperative.com) offers an AI-assisted mentoring and connection platform that matches employees for guided conversations covering career development, mentorship, community building, and change adoption.

Future of WorkHR TechSaaSNew York, US

Co-investorsVoyager CapitalAlly Bridge GroupCatalio Capital Management

Co-investorsCatalio Capital Management, LP

Co-investorsRA Capital

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.

Boston, US

Co-investorsAvalon BioVenturesPfizer Venture InvestmentsRA Capital

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates for people living with obesity.

BiotechHealthtech

Co-investorsAtlas VentureCatalio Capital Management, LP

BiotechRadnor, US

Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAvoro Capital AdvisorsCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more

A biopharmaceutical company developing targeted oncology medicines, with a focus on treatments for patients of all ages including children with cancers such as pediatric low-grade glioma (pLGG).

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)DONALD BERGSTROM(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)DAVID MOTT(Director)TIMOTHY LOWINGER(Executive Officer)EVA JACK(Executive Officer)

Co-investorsF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsEQT Life SciencesFrazier Life SciencesLSP (Life Sciences Partners)

Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.

Co-investorsAccess BiotechnologyLightstone VenturesPfizer Venture InvestmentsRA CapitalSV Health Investors

Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsEcoR1 CapitalForesite CapitalSofinnova VenturesThe Column Group

HealthtechCambridge, US

Matthew Shair(Director)R. Porter James(Executive Officer, Director)Alex Balcom(Executive Officer)

BoardAndrew Hack(Director)Cameron Wheeler(Director)Joseph Pearlberg(Director)

Co-investorsAvoro Capital Advisors

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US

Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in

Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPFifty Years+5 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Co-investorsAvoro Capital AdvisorsLightspeed Venture PartnersRA Capital

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsForesite CapitalKurma PartnersvenBio Partners

Clinical-stage company developing novel therapies for orphan renal diseases.

Co-investorsPureos BioventuresSR One Capital Management

HealthtechStamford, US

Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)

BoardStephen Squinto(Director)inDeval Patrick(Director)Carl L Gordon(Director)in

Co-investorsPfizer Venture InvestmentsOrbiMed

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapitalThe Column GroupCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsThird Rock VenturesGV (Google Ventures)

Co-investorsSofinnova Ventures

Co-investorsBain Capital Double Impact Fund LPBain Capital Venture

Co-investorsAtlas Venture

Co-investorsLux Capital

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets.

BiotechHealthtech

BiotechSan Diego, US

Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)Howard Foyt(Executive Officer)Donald J. Elmer(Director)

Co-investorsRA CapitalSanderling VenturesThe Vertical GroupRed Tree Venture